bay-11-7082 and Laryngeal-Neoplasms

bay-11-7082 has been researched along with Laryngeal-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bay-11-7082 and Laryngeal-Neoplasms

ArticleYear
NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer.
    International journal of oncology, 2011, Volume: 39, Issue:4

    Centrosome amplification can drive chromosomal instability (CIN) which is a major source of tumor initiation. The present study aimed to investigate the impact of nuclear factor kappa B (NF-κB) on centrosome amplification of Hep-2 cells. Immunofluorescence was performed to display centrosomes. BAY11-7082 was used as an inhibitor of NF-κB to assess the inhibition of centrosome amplification, and cyclin-dependent kinase 2 (CDK2), ensuring cell cycle cycle coordination with centrosome cycle was detected by Western blotting. Furthermore, a 1556-bp fragment of the CDK2 promoter was analyzed using the TRANSFAC-TESS software. Luciferase assay, including a series of truncated CDK2 promoters and site mutations, was carried out to determine NF-κB binding sites in the CDK2 promoter. Electrophoresis mobility shift and chromatin immunoprecipitation assays were applied to confirm whether NF-κB indeed binds to the 5'-promoter region of the CDK2 gene. To reveal the clinical significance of CDK2 expression in laryngeal squamous cell cancer, mRNA and protein levels were assessed by RT-PCR and Western blotting, respectively. We found that the transcription factor NF-κB plays a role in centrosome amplification in Hep-2 cells. Centrosome amplification is reduced by inhibition of the NF-κB pathway. Moreover, expression of the p65 subunit of NF-κB is sufficient to promote centrosome amplification and increase in CDK2 protein levels. We further identified a functional NF-κB binding site located in the CDK2 promoter. Single mutation of the NF-κB site III (construct mutIII) however resulted in 76±5% (p<0.01) luciferase activity reduction. Electromobility shift assays and chromatin immunoprecipitaton results suggest that NF-κB indeed binds to this responsive element associating with CDK2 expression and centrosome amplification. RT-PCR and Western blotting results revealed that both mRNA and protein levels of CDK2 were significantly higher in tumor tissues than those in paired adjacent normal laryngeal tissues.

    Topics: Base Sequence; Binding Sites; Cell Cycle; Cell Line, Tumor; Centrosome; Cyclin-Dependent Kinase 2; DNA-Binding Proteins; Gene Amplification; HEK293 Cells; Humans; Laryngeal Neoplasms; Molecular Sequence Data; Mutation; Neoplasms, Squamous Cell; NF-kappa B; Nitriles; Promoter Regions, Genetic; Protein Subunits; Sulfones; Transcriptional Activation; Transfection; Up-Regulation

2011